Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04599140 |
TitleSX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | Phase
Phase 1
|
Date Added 2020-10-22 |
Location
Texas, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
CXCR1/2 Inhibitor SX-682, Nivolumab |
Tags
MSS/ MMRp
|
| NCT ID NCT04724239 |
TitleA Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma | Phase
Phase 2
|
Date Added 2021-01-26 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
chidamide, IBI305, Sintilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT06566755 |
TitleCadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer | Phase
Phase 3
|
Date Added 2024-08-22 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06589440 |
TitlePhase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) | Phase
Phase 2
|
Date Added 2024-09-19 |
Location
New Jersey, United States
Texas, United States Washington, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Balstilimab, Botensilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT06493760 |
TitleA Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | Phase
Phase 2
|
Date Added 2024-07-10 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06513221 |
TitleA Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab | Phase |
Date Added 2024-07-22 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status |
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06788171 |
TitlePULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM | Phase
Phase 2
|
Date Added 2025-03-25 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06794086 |
TitleSBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases | Phase
Phase 3
|
Date Added 2025-01-27 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06792695 |
TitleA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Phase
Phase 2
|
Date Added 2025-03-25 |
Location
Arizona, United States
California, United States District of Columbia, United States Illinois, United States Maryland, United States Massachusetts, United States Minnesota, United States New York, United States Ohio, United States Texas, United States Australia Canada China France Germany Italy Korea, Republic of Spain Taiwan United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06801665 |
TitleFMT+ QL1706+bevacizumab+ XELOX As First-line Treatment for Advanced MSS-type Colon Cancer with Liver Metastasis | Phase
Phase 2
|
Date Added 2025-01-30 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
